(NASDAQ: AUPH) Aurinia Pharmaceuticals's forecast annual revenue growth rate of 13.85% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.03%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.48%.
Aurinia Pharmaceuticals's revenue in 2026 is $311,507,000.On average, 9 Wall Street analysts forecast AUPH's revenue for 2026 to be $43,844,351,391, with the lowest AUPH revenue forecast at $41,724,846,285, and the highest AUPH revenue forecast at $45,403,711,080. On average, 9 Wall Street analysts forecast AUPH's revenue for 2027 to be $52,108,159,436, with the lowest AUPH revenue forecast at $46,940,452,070, and the highest AUPH revenue forecast at $63,901,814,967.
In 2028, AUPH is forecast to generate $61,397,791,985 in revenue, with the lowest revenue forecast at $51,504,107,133 and the highest revenue forecast at $78,548,087,540.